# HGH Fragment 176-191 (AOD-9604)

*Also known as: AOD-9604, HGH Frag, AOD9604, Fragment 176-191*

Modified fragment of the growth hormone C-terminus studied for lipolysis without growth effects.

## Overview

HGH Fragment 176-191 (AOD-9604) is a modified synthetic peptide corresponding to the C-terminal region of human growth hormone (residues 177-191), engineered to retain the fat-burning (lipolytic) activity of full-length HGH without its growth-promoting and insulin-regulating effects. It is proposed to act on the beta-3 adrenergic pathway to stimulate lipolysis in adipose tissue. Its estimated half-life is roughly 12 hours with around 50% bioavailability, which in research contexts supports once or twice daily dosing. The evidence picture is mixed. AOD-9604 did reach Phase 2 human trials for obesity and showed some weight-loss signal without significant safety issues, but development was discontinued, and the compound is not an approved medication.

## Pharmacokinetics

- **Model tier:** simple
- **Half-life:** 0.5 days (12 hours)
- **Bioavailability:** 50%

## Dosing

- **Default dose:** 0.5 mg
- **Typical range:** 0.25–1 mg
- **Units:** ng/mL

## Source

- **Label:** Estimated
- **Notes:** C-terminal HGH fragment; lipolytic in studies, human PK limited.

**Tags:** weight-loss

---

**Canonical URL:** https://anabolicdex.com/compounds/hgh-frag-176-191
**Plot:** https://anabolicdex.com/plot?compound=hgh-frag-176-191